BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22835617)

  • 1. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study.
    Bradley JM; Blume SW; Balp MM; Honeybourne D; Elborn JS
    Eur Respir J; 2013 Mar; 41(3):571-7. PubMed ID: 22835617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
    Quittner AL; Modi AC; Wainwright C; Otto K; Kirihara J; Montgomery AB
    Chest; 2009 Jun; 135(6):1610-1618. PubMed ID: 19447923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes.
    Cheney J; Vidmar S; Gailer N; Wainwright C; Douglas TA;
    J Cyst Fibros; 2020 May; 19(3):483-491. PubMed ID: 32165156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference?
    Yi MS; Tsevat J; Wilmott RW; Kotagal UR; Britto MT
    J Pediatr; 2004 Jun; 144(6):711-8. PubMed ID: 15192614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sinonasal quality-of-life declines in cystic fibrosis patients with pulmonary exacerbations.
    Safi C; DiMango E; Keating C; Zhou Z; Gudis DA
    Int Forum Allergy Rhinol; 2020 Feb; 10(2):194-198. PubMed ID: 31834674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective pilot study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised controlled trial.
    Choyce J; Shaw KL; Sitch AJ; Mistry H; Whitehouse JL; Nash EF
    BMC Pulm Med; 2017 Jan; 17(1):22. PubMed ID: 28114922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing quality of life and disease severity in Hungarian children and young adults with cystic fibrosis.
    Bodnar R; Kadar L; Holics K; Ujhelyi R; Kovacs L; Bolbas K; Szekely G; Gyurkovits K; Solyom E; Meszaros A
    Ital J Pediatr; 2014 Jun; 40():50. PubMed ID: 24887479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis.
    Habib AR; Manji J; Wilcox PG; Javer AR; Buxton JA; Quon BS
    Ann Am Thorac Soc; 2015 Mar; 12(3):420-8. PubMed ID: 25642976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis.
    Solem CT; Vera-Llonch M; Liu S; Botteman M; Castiglione B
    Health Qual Life Outcomes; 2016 Apr; 14():63. PubMed ID: 27097977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up.
    van Horck M; Winkens B; Wesseling G; de Winter-de Groot K; de Vreede I; Jöbsis Q; Dompeling E
    Eur J Pediatr; 2017 Aug; 176(8):1047-1054. PubMed ID: 28597092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal trends in health-related quality of life in adults with cystic fibrosis.
    Dill EJ; Dawson R; Sellers DE; Robinson WM; Sawicki GS
    Chest; 2013 Sep; 144(3):981-989. PubMed ID: 23670667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.
    Girón-Moreno RM; Justicia JL; Yamamoto S; Valenzuela C; Cisneros C; Gómez-Punter RM; Fernandes-Vasconcelos G; Ancochea J
    BMC Pulm Med; 2014 Sep; 14():150. PubMed ID: 25248567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
    BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchiectases at early chest computed tomography in children with cystic fibrosis are associated with increased risk of subsequent pulmonary exacerbations and chronic pseudomonas infection.
    Bortoluzzi CF; Volpi S; D'Orazio C; Tiddens HA; Loeve M; Tridello G; Assael BM
    J Cyst Fibros; 2014 Sep; 13(5):564-71. PubMed ID: 24726420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of care and clinical condition in paediatric cystic fibrosis patients.
    Baumann U; Stocklossa C; Greiner W; von der Schulenburg JM; von der Hardt H
    J Cyst Fibros; 2003 Jun; 2(2):84-90. PubMed ID: 15463855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.